# Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

> **NCT00413660** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 509 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00413660
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 509 (ACTUAL)
- **Last updated:** 2013-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00413660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00413660, "Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00413660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*